Sanofi Price to Book Ratio 2010-2024 | SNY

Historical price to book ratio values for Sanofi (SNY) over the last 10 years. The current price to book ratio for Sanofi as of June 19, 2024 is 1.48.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Sanofi Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-06-18 47.22 inf
2024-03-31 46.65 0.00
2023-12-31 47.73 $31.81 1.50
2023-09-30 51.49 0.00
2023-06-30 51.74 $31.50 1.64
2023-03-31 50.34 0.00
2022-12-31 44.80 $31.40 1.43
2022-03-31 45.96 0.00
2021-09-30 43.16 0.00
2021-03-31 42.66 0.00
2020-09-30 43.27 0.00
2020-03-31 36.39 0.00
2019-09-30 38.56 0.00
2019-03-31 35.37 0.00
2018-03-31 30.56 0.00
2017-12-31 32.79 $26.26 1.25
2017-09-30 37.97 0.00
2017-06-30 36.53 $25.22 1.45
2017-03-31 33.37 0.00
2016-12-31 29.83 $24.72 1.21
2016-09-30 28.17 0.00
2016-06-30 30.87 $23.85 1.29
2016-03-31 28.41 0.00
2015-09-30 33.58 0.00
2015-06-30 35.04 $23.95 1.46
2014-06-30 36.43 0.00
2013-06-30 34.07 0.00
2022-06-30 46.28 0.00
2012-06-30 24.14 0.00
2012-03-31 23.66 0.00
2011-12-31 22.31 0.00
2011-09-30 20.02 0.00
2011-06-30 24.52 0.00
2011-03-31 20.78 0.00
2010-12-31 19.02 0.00
2010-09-30 19.62 0.00
2010-06-30 17.74 0.00
2010-03-31 21.27 0.00
2009-12-31 22.35 0.00
2009-09-30 21.03 0.00
2009-06-30 16.79 0.00
2009-03-31 15.07 0.00
2022-09-30 35.17 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11